With our singular focus on autoimmune diseases with unmet needs, we deliver transformative therapies that enable patients to live their fullest lives. We are a proven, passionate team committed to changing the trajectory of autoimmune diseases. Find out more about who we are, what drives us, and what we’ve accomplished so far.

Aurinia is a genus of flowering plants of the family Brassicaceae (Cruciferae), native to mountainous areas of Central and Southern Europe, Russia and Turkey. They are closely related to Alyssum, which they resemble. They can either …

At Aurinia, we embrace the possibility to change the trajectory of autoimmune diseases with unmet medical needs. Our mission and vision are our North Star, directing all that we do to help patients thrive.

Aurinia is committed to delivering transformative therapies that address the unmet needs of patients living with autoimmune diseases today – and developing the breakthrough therapies of tomorrow. Our work is rooted in science and at the leading edge of approaches for the treatment of autoimmune and inflammatory diseases.

关于Aurinia. Aurinia Pharmaceuticals总部位于加拿大，是一家完全集成的生物制药公司，现阶段专注于罕见的自身免疫性疾病和肾脏相关疾病，在狼疮肾炎方面有很强的影响力。

2019年1月16日 · Aurinia是一家临床阶段的生物制药公司，致力于开发和商业化未满足医疗需求疾病领域的治疗方法。 Aurinia Pharmaceuticals, Inc.目前正在开发用于治疗狼疮性肾炎（LN）和局灶性节段性肾小球硬化（FSGS）的研究药物voclosporin——一种钙调神经磷酸酶抑制剂。

作为一家生物制药公司(原Isotechnika制药公司)，Aurinia制药公司致力于开发治疗自身免疫性疾病的药物，特别是狼疮性肾炎(LN)的临床研究及管理。 这家公司在2017年涨势惊人。

2024年7月18日 · Aurinia Pharmaceuticals是一家专注于肾脏疾病的治疗的生物制药公司。 该公司目前只有一项资产， 即有史以来第一款获得 FDA 批准的狼疮肾炎口服疗法--降钙素酶抑制剂（CNI） 免疫抑制剂 Lupkynis（voclosporin）- 在 2021 年 1 月获得批准后的销售。

2024年11月7日 · After an activist investor revolted against the leadership team at Aurinia Pharmaceuticals, the CEO in question is resorting to restructuring. Aurinia on Thursday unveiled a strategic overhaul...

2024年11月15日 · Aurinia is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. In January 2021, the Company introduced LUPKYNIS® (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis.